Journal
CLINICAL RHEUMATOLOGY
Volume 42, Issue 5, Pages 1267-1274Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-022-06490-8
Keywords
Axial spondyloarthritis; HLA-B27; TNF inhibition; Treatment response
Categories
Ask authors/readers for more resources
This study aimed to investigate the impact of HLA-B27 on TNFi effectiveness in axSpA patients. The results showed that HLA-B27 negative patients had a higher risk of drug discontinuation in TNFi treatment, while male sex and elevated CRP levels were associated with longer drug retention. Therefore, HLA-B27 genotype is an important predictor of treatment effectiveness, while male sex and CRP levels may better describe the variability of response in individual patients.
Objective To explore the impact of the human leucocyte antigen (HLA)-B27 on the effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). Methods A total of 1109 patients with available HLA-B27 status (831 B27+ patients and 278 B27- patients) fulfilling the Assessment of Spondyloarthritis international Society classification criteria for axSpA from the prospective Swiss Clinical Quality Management Registry initiating a first TNFi were included. Drug retention was investigated with multiple adjusted Cox proportional hazard models with imputation of missing values. Multiple-adjusted logistic regression analyses were used to assess the proportion of patients reaching 50% reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) at 1 year. Results B27+ and B27- patients differed with regard to age, sex, BASDAI, C-reactive protein (CRP), body mass index, enthesitis, uveitis, and classification status. After adjustment for potential confounders for the relationship between HLA-B27 and drug effectiveness (sex and family history of spondyloarthritis), a higher risk of drug discontinuation was found in B27- patients (HR 1.53, 95% CI 1.27-1.83). This difference decreased after additional adjustment for parameters which may act as mediators (HR 1.30, 95% CI 1.30-1.55). Male sex and elevated C-reactive protein (CRP) levels were consistently associated with longer retention. Comparable results were obtained for BASDAI50 responses. Conclusion The HLA-B27 genotype is an important predictor of treatment effectiveness. Male sex and CRP seem, however, to better describe variability of response in individual patients. This data may help avoiding potential discrimination of B27- individuals with regard to TNFi initiation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available